Legend Biotech’s deal with Novartis is a reminder that biotech’s bear market has a few haves, and many have-nots

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the latest twist in the Ozempic panic, polarizing data in genome editing, and another biotech in search of “strategic alternatives.”

The Ozempic panic might be waning
The foregone conclusion that GLP-1 medicines will dramatically reshape global business has led to dramatic changes in valuations in a disparate group of industries. And then, following this weekend, when Novo Nordisk finally presented detailed data from a key clinical trial, a strange thing happened: Medical devices stocks went up.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In